Assessment on Safety of New Oral Anticoagulants for Nonvalvular Atrial Fibrillation – A Single Medical Center Experience

• Main Authors: Ying-HsuanLai, 賴穎萱
• Other Authors: Yea-Huei Kao Yang
• Format: Others
• Language: zh-TW
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/d35hge

碩士 === 國立成功大學 === 臨床藥學與藥物科技研究所 === 102 === Although new oral anticoagulants (NOACs), dabigatran and rivaroxaban, are recommended for prevention of thromboembolism in patients with atrial fibrillation especially those who cannot tolerate warfarin, safety information in Taiwan population is limited. Meanwhile, relative bleeding risk between NOACs remains unknown due to lack of head-to-head comparison. To investigate the bleeding risk of dabigatran and rivaroxaban and to compare safety between NOACs and warfarin, we conducted a retrospective cohort study in patients who had nonvalvular atrial fibrillation. In total, we included 437 patients. The crude rate of total bleeding was 27.57 per 100 person-years in rivaroxaban group, 28.25 per 100 person-years in dabigatran group and 37.74 per 100 person-years in warfarin group. No significant differences were found between two study drugs and warfarin, although the incidences of total bleeding of NOACs were lower than warfarin. However, there seemed to be more adverse events in NOACs than in warfarin. Because of small sample size and short follow-up duration, we cannot conclude the safety differences between NOACs and warfarin. Further studies in Taiwan population are warranted.